Postencephalitic Parkinsonism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for postencephalitic parkinsonism. 157 active patents protecting 2 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

2
Approved drugs
157
Active US patents
53/100
Avg vulnerability
Annual revenue covered

Originators in Postencephalitic Parkinsonism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Aton 151 patents Merz 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating postencephalitic parkinsonism. Each bar = one year. Y-axis scaled to peak year (64 patents).

32
28
1
29
4
32
1
33
64
34
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sinemet Cr
CARBIDOPA
Aton 151 53 2028-12-26
Inbrija
LEVODOPA
Merz 6 53 2029-02-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE43711 Inbrija method of use 75 2029-02-03
12458615 Inbrija method of use 75 2033-10-21
8377474 Sinemet Cr method of use 58 2028-12-26
9089607 Sinemet Cr method of use 58 2028-12-26
9089607 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26
9533046 Sinemet Cr method of use 58 2028-12-26
9533046 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303605 Sinemet Cr formulation 38 2034-10-07
12178918 Sinemet Cr formulation 38 2034-10-07
11357733 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12178918 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07

Related